Titelia

Funds holding ERNEXA THERAPEUTICS INC

ISIN US1140823089 · United States

Fund holders
1
Of which ETFs
0 1 other fund
Value held
≈ 16.1K $ 13.7K €

A single tracked fund declares this company. So these figures do not say who owns it.

FundSharesValueWeight in fund
CINVEST,FI CINVEST/ AZERO GLOBAL GESALCALA, S.A., S.G.I.I.C. 13.7K €0.98 %as of Dec 31, 2025 ↗

Download this table: CSV, JSON

Report an error

The funds most exposed to it

The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.

FundWeight in fund
CINVEST,FI CINVEST/ AZERO GLOBAL GESALCALA, S.A., S.G.I.I.C. 0.98 %as of Dec 31, 2025 ↗

Quarter after quarter

Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.

QuarterHoldersChangeSharesChange
2026Q25045,115+68.6 %
2026Q15+126,766-0.2 %
2025Q44+326,809+1,148.7 %
2025Q312,147

Institutional managers

17 managers declare this company to the SEC (Form 13F).

ManagerSharesValue
Bleichroeder LP2,000,000398K $as of Mar 31, 2026
Dauntless Investment Group, LLC612,443121.9K $as of Mar 31, 2026
Corient Private Wealth LLC438,09387.2K $as of Mar 31, 2026
GEODE CAPITAL MANAGEMENT, LLC244,44648.6K $as of Mar 31, 2026
XTX Topco Ltd54,33810.8K $as of Mar 31, 2026
Warberg Asset Management LLC50,00010.1K $as of Mar 31, 2026
JANE STREET GROUP, LLC41,1678.2K $as of Mar 31, 2026
CITADEL ADVISORS LLC33,0766.6K $as of Mar 31, 2026
UBS Group AG21,2334.2K $as of Mar 31, 2026
GOLDMAN SACHS GROUP INC16,6313.3K $as of Mar 31, 2026
Sippican Capital Advisors10,0002K $as of Mar 31, 2026
BlackRock, Inc.820163 $as of Mar 31, 2026
ASSETMARK, INC13326 $as of Mar 31, 2026
BNP PARIBAS FINANCIAL MARKETS102 $as of Mar 31, 2026
MONTAG A & ASSOCIATES INC82 $as of Mar 31, 2026
SBI Securities Co., Ltd.61 $as of Mar 31, 2026
Activest Wealth Management31 $as of Mar 31, 2026
Cite this page

Titelia. "Funds holding ERNEXA THERAPEUTICS INC". https://titelia.com/en/stocks/ernexa-therapeutics-inc-US1140823089